NZ703347A - Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism - Google Patents

Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Info

Publication number
NZ703347A
NZ703347A NZ703347A NZ70334713A NZ703347A NZ 703347 A NZ703347 A NZ 703347A NZ 703347 A NZ703347 A NZ 703347A NZ 70334713 A NZ70334713 A NZ 70334713A NZ 703347 A NZ703347 A NZ 703347A
Authority
NZ
New Zealand
Prior art keywords
secondary hyperparathyroidism
dihydroxyvitamin
methylene
treat secondary
symptoms
Prior art date
Application number
NZ703347A
Other languages
English (en)
Inventor
Hector F Deluca
Margaret Clagett-Dame
Lori A Plum
Julia B Zella
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of NZ703347A publication Critical patent/NZ703347A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ703347A 2012-06-29 2013-03-14 Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism NZ703347A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
NZ703347A true NZ703347A (en) 2016-05-27

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703347A NZ703347A (en) 2012-06-29 2013-03-14 Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Country Status (19)

Country Link
US (4) US9205096B2 (OSRAM)
EP (1) EP2866811A1 (OSRAM)
JP (1) JP2015522015A (OSRAM)
KR (1) KR20150030673A (OSRAM)
CN (1) CN104394871A (OSRAM)
AU (1) AU2013281217B2 (OSRAM)
BR (1) BR112014032847A2 (OSRAM)
CA (1) CA2877680C (OSRAM)
CL (1) CL2014003565A1 (OSRAM)
CO (1) CO7240358A2 (OSRAM)
HK (1) HK1206600A1 (OSRAM)
IL (1) IL236184A0 (OSRAM)
MX (1) MX2015000076A (OSRAM)
MY (1) MY172886A (OSRAM)
NZ (1) NZ703347A (OSRAM)
RU (1) RU2666995C2 (OSRAM)
SG (1) SG11201408731WA (OSRAM)
WO (1) WO2014003849A1 (OSRAM)
ZA (1) ZA201500119B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1206600A1 (en) * 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
CN105765592B (zh) 2013-09-27 2019-12-17 科德克希思公司 用于酶变体的自动筛选的方法、装置和系统
JP6309086B2 (ja) * 2013-09-27 2018-04-11 コデクシス， インコーポレイテッド 構造ベース予測モデリング
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10369161B2 (en) * 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
AU2001247619A1 (en) 2000-03-27 2001-10-08 Wisconsin Alumni Research Foundation Vitamin d compounds used to stabilize kidney transplants
EP1301189A2 (en) 2000-07-14 2003-04-16 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
KR20060040744A (ko) * 2003-09-19 2006-05-10 화이자 프로덕츠 인크. 쇠약, 근육 손상 또는 근육감소증 치료용2-알킬리덴-19-노르-비타민 ｄ 유도체
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
CA2597624C (en) 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US8604009B2 (en) 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
HK1206600A1 (en) * 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Also Published As

Publication number Publication date
US9034853B2 (en) 2015-05-19
MX2015000076A (es) 2015-04-10
CN104394871A (zh) 2015-03-04
US9205096B2 (en) 2015-12-08
BR112014032847A2 (pt) 2017-06-27
US20140005152A1 (en) 2014-01-02
CA2877680A1 (en) 2014-01-03
CL2014003565A1 (es) 2015-08-28
MY172886A (en) 2019-12-13
US20140187522A1 (en) 2014-07-03
AU2013281217B2 (en) 2017-03-02
ZA201500119B (en) 2017-11-29
AU2013281217A1 (en) 2015-01-22
KR20150030673A (ko) 2015-03-20
IL236184A0 (en) 2015-01-29
RU2015102831A (ru) 2016-08-20
CA2877680C (en) 2017-08-29
US9717744B2 (en) 2017-08-01
EP2866811A1 (en) 2015-05-06
SG11201408731WA (en) 2015-01-29
JP2015522015A (ja) 2015-08-03
US20170252360A1 (en) 2017-09-07
US10046000B2 (en) 2018-08-14
CO7240358A2 (es) 2015-04-17
US20160136184A1 (en) 2016-05-19
WO2014003849A1 (en) 2014-01-03
HK1206600A1 (en) 2016-01-15
RU2666995C2 (ru) 2018-09-13

Similar Documents

Publication Publication Date Title
NZ703347A (en) Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
MY183449A (en) Formulations of quinones for the treatment of ophthalmic diseases
CO6630086A2 (es) Tratamiento de artritis por lupus usando laquinimod
PH12015502075A1 (en) Treatment of cataplexy
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
MX2015007479A (es) Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas.
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
NZ599833A (en) Method of preventing type 1 diabetes
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12014502065A1 (en) Vesicular formulations
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
IN2014MN01806A (OSRAM)
BR112022019168A2 (pt) Tratamento de distúrbios respiratórios
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
BR112018002763A2 (pt) método para cicatrização de ferimentos
IN2014MN02382A (OSRAM)
PH12014500684A1 (en) Treatment of rhinitis
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment
UA52511U (ru) Способ лечения псориаза
WO2013158698A3 (en) Method treating scleroderma

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY CPA GLOBAL

Effective date: 20170203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY CPA GLOBAL

Effective date: 20180201

LAPS Patent lapsed